(NASDAQ: OCUL) Ocular Therapeutix's forecast annual revenue growth rate of 30.96% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Ocular Therapeutix's revenue in 2025 is $63,723,000.On average, 5 Wall Street analysts forecast OCUL's revenue for 2025 to be $11,408,255,856, with the lowest OCUL revenue forecast at $10,964,583,793, and the highest OCUL revenue forecast at $12,578,659,580. On average, 4 Wall Street analysts forecast OCUL's revenue for 2026 to be $12,699,516,486, with the lowest OCUL revenue forecast at $11,497,308,314, and the highest OCUL revenue forecast at $15,600,082,235.
In 2027, OCUL is forecast to generate $25,198,028,854 in revenue, with the lowest revenue forecast at $21,372,589,728 and the highest revenue forecast at $28,957,950,815.